One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
I-Mab logo
I-Mab IMAB
report update icon

Quarterly report 2023-Q4
added 10-28-2026

I-Mab Balance Sheet 2025-2011 | IMAB

Brief overview of I-Mab's balance sheet structure

This overview follows the five latest available annual observations between 2018 and 2023.

Assets grew from 2.4 billion CNY to 2.6 billion CNY. An increase of +10% at roughly 1.9% CAGR was not especially fast.

Liability growth of +115.3% exceeded asset growth of +10%, increasing reliance on outside funding.

The equity-to-assets ratio is 65.8%, compared with -40.2% five periods ago. The balance sheet has a substantial internal cushion.

The period ended with net cash: net debt stood at -2.1 billion CNY. This supports financial flexibility.

The cash reserve occupies 82% of the balance sheet, previously 70.7%. It is one marker of short-term resilience.

The accumulated result is -8.3 billion CNY and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.

What the balance sheet shows

I-Mab's balance sheet is broadly resilient, though selected areas require monitoring. The balance between assets, equity and liabilities remains the key issue.

Annual Balance Sheet I-Mab

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- - -2.1 B -3.16 B -3.41 B - -1.06 B -1.61 B -94.9 M - - - - - -

Long Term Debt

- - 23.1 M 32.1 M 81.8 M - 68.2 M 67 M 114 M - - - - - -

Long Term Debt Current

- - 21.9 M 24 M 30.7 M 8.06 M 6.81 M - - - - - - - -

Total Non Current Liabilities

- - 483 M 406 M 418 M 131 M 79.6 M 2.98 B 1.13 B - - - - - -

Total Current Liabilities

- - 412 M 758 M 624 M 576 M 588 M 346 M - - - - - - -

Total Liabilities

- - 895 M 1.16 B 1.04 B 707 M 668 M 416 M 1.33 B - - - - - -

Deferred Revenue

- - 2.2 M 8.68 M - - 563 K 14.2 M 15.8 M - - - - - -

Retained Earnings

- - -8.33 B -6.86 B -4.35 B -2.02 B -2.49 B -1.01 B -358 M - - - - - -

Total Assets

- - 2.61 B 4.07 B 5.6 B 6.33 B 1.74 B 2.38 B 1.03 B - - - - - -

Cash and Cash Equivalents

- - 2.14 B 3.21 B 3.52 B 4.76 B 1.14 B 1.68 B 413 M - - - - - -

Book Value

- - 1.72 B 2.91 B 4.56 B 5.63 B 1.07 B 1.96 B -300 M - - - - - -

Total Shareholders Equity

- - 1.72 B 2.91 B 4.56 B 5.63 B -2.03 B -955 M -300 M - - - - - -

All numbers in CNY currency

Quarterly Balance Sheet I-Mab

2025-Q4 2025-Q3 2025-Q2 2024-Q4 2023-Q4 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - 23.1 M 32.1 M - 61.3 M - 81.8 M - - - 5.54 M 5.18 M - - 7.49 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - 483 M 406 M - 385 M - 418 M - - - 131 M 207 M - - 79.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - - - 895 M 1.16 B - 975 M - 1.04 B - - - 707 M 556 M - - 668 M - - - 416 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - 2.2 M 8.68 M - - - - - - - - - - - - - - - 14.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - -8.33 B -6.86 B - -5.4 B - -4.35 B - - - -2.02 B -3.06 B - - -2.49 B - - - -1.01 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - - 2.61 B 4.07 B - 4.99 B - 5.6 B - - - 6.33 B 4.3 B - - 1.74 B - - - 2.38 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - - 2.2 B 3.31 B - 3.71 B - 3.52 B - - - 4.76 B 2.96 B - - 1.19 B 1.28 B - - 1.59 B - - - 413 M - - - 64.1 M - - - - - - - - - - - - - - - - - - - - - - -

Book Value

- - - - 1.72 B 2.91 B - 4.02 B - 4.56 B - - - 5.63 B 3.74 B - - 1.07 B - - - 1.96 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - - 1.72 B 2.91 B - 4.02 B - 4.56 B - - - 5.63 B 3.74 B - - -2.03 B -1.63 B - - -955 M - - - -300 M - - - -14.5 M - - - - - - - - - - - - - - - - - - - - - - -

All numbers in CNY currency

Balance Sheet is a fundamental financial report of I-Mab, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Reata Pharmaceuticals Reata Pharmaceuticals
RETA
- - $ 6.29 B usaUSA
ObsEva SA ObsEva SA
OBSV
- -15.52 % $ 10.5 M schweizSchweiz
PolarityTE PolarityTE
PTE
- -0.82 % $ 1.78 M usaUSA
Kronos Bio Kronos Bio
KRON
- 1.49 % $ 50.8 M usaUSA
Landos Biopharma Landos Biopharma
LABP
- 0.58 % $ 144 M usaUSA
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
- -0.04 % $ 2.62 B usaUSA
Poseida Therapeutics Poseida Therapeutics
PSTX
- - $ 857 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Trevena Trevena
TRVN
- -46.58 % $ 31.8 M usaUSA
Immunovant Immunovant
IMVT
$ 35.73 1.65 % $ 6.52 B usaUSA
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
Oncorus Oncorus
ONCR
- -8.54 % $ 3.19 M usaUSA
Y-mAbs Therapeutics Y-mAbs Therapeutics
YMAB
- - $ 382 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
- -2.99 % $ 2.47 M usaUSA
InMed Pharmaceuticals InMed Pharmaceuticals
INM
$ 15.56 13.57 % $ 64.8 M canadaCanada
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
- - $ 23.9 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Satsuma Pharmaceuticals Satsuma Pharmaceuticals
STSA
- -0.9 % $ 36.5 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 1.14 -6.97 % $ 97.2 M usaUSA
SpringWorks Therapeutics SpringWorks Therapeutics
SWTX
- - $ 3.48 B usaUSA
Metacrine Metacrine
MTCR
- - $ 24.2 M usaUSA
Turning Point Therapeutics Turning Point Therapeutics
TPTX
- -0.13 % $ 3.73 B usaUSA
Infinity Pharmaceuticals Infinity Pharmaceuticals
INFI
- -46.98 % $ 3.57 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
- 31.87 % $ 1.61 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Morphic Holding Morphic Holding
MORF
- - $ 2.42 B usaUSA
Novan Novan
NOVN
- -24.84 % $ 2.64 M usaUSA
Genocea Biosciences Genocea Biosciences
GNCA
- -15.0 % $ 3.04 M usaUSA
Eiger BioPharmaceuticals Eiger BioPharmaceuticals
EIGR
- -9.21 % $ 2.55 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
BELLUS Health BELLUS Health
BLU
- - $ 2.47 B canadaCanada
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Intra-Cellular Therapies Intra-Cellular Therapies
ITCI
- - $ 13.6 B usaUSA
IGM Biosciences IGM Biosciences
IGMS
- - $ 76.9 M usaUSA
Marinus Pharmaceuticals Marinus Pharmaceuticals
MRNS
- - $ 29.6 M usaUSA
Merrimack Pharmaceuticals Merrimack Pharmaceuticals
MACK
- - $ 216 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
- - $ 728 M usaUSA
Rubius Therapeutics Rubius Therapeutics
RUBY
- -33.55 % $ 7.81 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
TRACON Pharmaceuticals TRACON Pharmaceuticals
TCON
- -1.38 % $ 46.8 M usaUSA
Mirati Therapeutics Mirati Therapeutics
MRTX
- - $ 3.3 B usaUSA
Revance Therapeutics Revance Therapeutics
RVNC
- - $ 309 M usaUSA
Allogene Therapeutics Allogene Therapeutics
ALLO
$ 0.93 -11.99 % $ 205 M usaUSA
InVivo Therapeutics Holdings Corp. InVivo Therapeutics Holdings Corp.
NVIV
- -37.48 % $ 476 K usaUSA
Epizyme Epizyme
EPZM
- - $ 249 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA